High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
Thirteen patients with relapsed acute leukemia, 12 adults with acute nonlymphocytic leukemia, and one child with acute lymphoblastic leukemia were treated with VP 16-213, an epipodophyllotoxin analog, at a dose of 200-300 mg/m2/day X5 as a 2-hour intravenous infusion. Only four patients achieved bone marrow aplasia and three regenerated with leukemic cells. The fourth patient achieved a partial remission for 4 weeks. Toxicities included myelosuppression (WBC nadir 500/microliter), nausea and vomiting (70% of courses), mucositis (23%), esophagitis (12%), which contributed to death in one patient, hypotension (12%), and transient liver function abnormalities (12%). It is concluded that increasing the dose of VP 16-213 as employed in this study did not increase the therapeutic activity of VP 16-213 for the treatment of relapsed leukemia but did increase the risk of toxicity.
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D004341:Drug Evaluation; D004941:Esophagitis / Q000139:chemically induced; D005047:Etoposide / Q000627:therapeutic use*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009325:Nausea / Q000139:chemically induced; D010865:Pilot Projects; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D005047:Etoposide; D011034:Podophyllotoxin